secondary aml Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 2 (1)

Interventional (1)

Roswell Park Cancer Institute (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadmyelodysplastic syndrome

I am/have/hadt-aml

I am/have/hadmyeloid leukemia

I am/have/hadacute myeloid leukemia with myelodysplasia-related changes

I am/have/hadmyelodysplasia

I am/have/hadsecondary acute myeloid leukemia

I am/have/hadmyelodysplastic syndrome acute myeloid leukemia

I am/have/hadcancer

I am/have/hadaml

I am/have/hadejection fraction

I am/have/hadleukemia

I am/have/hadplasma creatinine

I am/have/hadtreatment related aml

I am/have/hadtreatment related acute myeloid leukemia

I am/have/hadchronic myelomonocytic leukemia

I am/have/hadacute myeloid leukemia

added new label for I am/have/had

more

I am looking for

I am looking fordaunorubicin

I am looking forcytarabine

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by …

myelodysplastic syndrome

t-aml

daunorubicin

myeloid leukemia

acute myeloid leukemia with myelodysplasia-related changes

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.